Insider Transactions in Q2 2023 at Heron Therapeutics, Inc. (HRTX)

Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
May 22 2023	Craig A Collard Chief Executive Officer	SELL Payment of exercise price or tax liability	Direct	691 -1.82%	$691 $1.45 P/Share
Apr 13 2023	David Leslie Szekeres EVP, Chief Operating Officer	SELL Payment of exercise price or tax liability	Direct	2,012 -6.29%	$4,024 $2.88 P/Share
Apr 13 2023	David Leslie Szekeres EVP, Chief Operating Officer	BUY Exercise of conversion of derivative security	Direct	5,814 +8.43%	-
Apr 13 2023	Kimberly Manhard EVP, Drug Development	SELL Payment of exercise price or tax liability	Direct	1,417 -4.76%	$2,834 $2.88 P/Share
Apr 13 2023	Kimberly Manhard EVP, Drug Development	BUY Exercise of conversion of derivative security	Direct	5,814 +9.02%	-
Apr 13 2023	Lisa Peraza VP, Chief Accounting Officer	SELL Payment of exercise price or tax liability	Direct	860 -3.5%	$1,720 $2.88 P/Share
Apr 13 2023	Lisa Peraza VP, Chief Accounting Officer	BUY Exercise of conversion of derivative security	Direct	2,484 +4.84%	-
Apr 13 2023	John Poyhonen President & CCO	SELL Payment of exercise price or tax liability	Direct	2,012 -4.13%	$4,024 $2.88 P/Share
Apr 13 2023	John Poyhonen President & CCO	BUY Exercise of conversion of derivative security	Direct	5,814 +5.67%	-

Receive a notification when an Institution or Guru buys or sells HRTX shares.

Notify only if

Value

Get notified when an Heron Therapeutics, Inc. insider buys or sells HRTX shares.

Notify only if

Operation

Value

Type

Receive news related to HERON THERAPEUTICS, INC.